IRVINE, Calif., April 14, 2025--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced the company’s SAPIEN M3 mitral valve replacement system received CE Mark for the ...
Edwards Lifesciences EW announced that the FDA approved its SAPIEN M3 transcatheter mitral valve replacement system, making it the first minimally invasive, catheter-based treatment that uses a ...
The U.S. Food and Drug Administration has approved Edwards Lifesciences' SAPIEN 3 platform, a transcatheter aortic valve replacement (TAVR) therapy, for patients with severe aortic stenosis without ...
As legal battles continue between the manufacturers, the COMPARE-TAVI 1 trial has demonstrated that the Myval and Myval Octacor transcatheter heart valves (Meril Life Sciences) compare favorably with ...
This is for you, PrimalScript fans: My contacts at Sapien allowed me to leak a few teasers about the next version of PrimalScript that will hit the streets around August 1. The new 2007 release of ...
SAN FRANCISCO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results